targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000065518 | MONDO_0005148 | NCT01196546 | Completed | 4 | 2010-03-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,721,121 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01517412 | Completed | 3 | 2012-02-01 | null | null | null | Phase III+ | Phase II+ | 824,633,721,533 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01517412 | Completed | 3 | 2012-02-01 | null | null | null | Phase III+ | Phase II+ | 824,633,721,533 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01517412 | Completed | 3 | 2012-02-01 | null | null | null | Phase III+ | Phase II+ | 824,633,721,533 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00086515 | Completed | 3 | 2004-06-30 | null | null | null | Phase III+ | Phase II+ | 824,633,721,644 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00086515 | Completed | 3 | 2004-06-30 | null | null | null | Phase III+ | Phase II+ | 824,633,721,644 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00086515 | Completed | 3 | 2004-06-30 | null | null | null | Phase III+ | Phase II+ | 824,633,721,644 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02752113 | Completed | 3 | 2016-04-01 | null | null | null | Phase III+ | Phase II+ | 824,633,722,225 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02752113 | Completed | 3 | 2016-04-01 | null | null | null | Phase III+ | Phase II+ | 824,633,722,225 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02752113 | Completed | 3 | 2016-04-01 | null | null | null | Phase III+ | Phase II+ | 824,633,722,225 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01704261 | Completed | 3 | 2012-10-18 | null | null | null | Phase III+ | Phase II+ | 824,633,722,338 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01704261 | Completed | 3 | 2012-10-18 | null | null | null | Phase III+ | Phase II+ | 824,633,722,338 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01704261 | Completed | 3 | 2012-10-18 | null | null | null | Phase III+ | Phase II+ | 824,633,722,338 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00815399 | Completed | 4 | 2007-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,722,891 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00815399 | Completed | 4 | 2007-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,722,891 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00815399 | Completed | 4 | 2007-10-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,722,891 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00469092 | Completed | 4 | 2007-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,722,953 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00469092 | Completed | 4 | 2007-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,722,953 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00469092 | Completed | 4 | 2007-05-01 | null | null | Phase IV | Phase III+ | Phase II+ | 824,633,722,953 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00964184 | Completed | 4 | 2009-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 841,813,590,202 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00964184 | Completed | 4 | 2009-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 841,813,590,202 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00964184 | Completed | 4 | 2009-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 841,813,590,202 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01240759 | Completed | 2 | 2010-10-01 | null | null | null | null | Phase II+ | 841,813,590,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01240759 | Completed | 2 | 2010-10-01 | null | null | null | null | Phase II+ | 841,813,590,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01240759 | Completed | 2 | 2010-10-01 | null | null | null | null | Phase II+ | 841,813,590,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00121966 | Completed | 4 | 2003-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 841,813,590,557 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00121966 | Completed | 4 | 2003-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 841,813,590,557 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00121966 | Completed | 4 | 2003-01-01 | null | null | Phase IV | Phase III+ | Phase II+ | 841,813,590,557 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03332771 | Completed | 3 | 2017-12-01 | null | null | null | Phase III+ | Phase II+ | 841,813,591,202 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03332771 | Completed | 3 | 2017-12-01 | null | null | null | Phase III+ | Phase II+ | 841,813,591,202 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03332771 | Completed | 3 | 2017-12-01 | null | null | null | Phase III+ | Phase II+ | 841,813,591,202 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04317703 | Completed | 1 | 2020-08-19 | null | null | null | null | null | 876,173,328,564 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04317703 | Completed | 1 | 2020-08-19 | null | null | null | null | null | 876,173,328,564 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04317703 | Completed | 1 | 2020-08-19 | null | null | null | null | null | 876,173,328,564 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01972724 | Completed | 4 | 2013-12-16 | null | null | Phase IV | Phase III+ | Phase II+ | 893,353,198,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01972724 | Completed | 4 | 2013-12-16 | null | null | Phase IV | Phase III+ | Phase II+ | 893,353,198,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01972724 | Completed | 4 | 2013-12-16 | null | null | Phase IV | Phase III+ | Phase II+ | 893,353,198,265 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02020616 | Terminated | 1 | 2013-12-01 | Terminated | stopped | null | null | null | 893,353,198,627 | Lack of Efficacy | Phase 1/Phase 2 | 31/12/2013 | Terminated | 08/10/2019 | 28/02/2015 | Negative | Negative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02020616 | Terminated | 1 | 2013-12-01 | Terminated | stopped | null | null | null | 893,353,198,627 | Lack of Efficacy | Phase 1/Phase 2 | 31/12/2013 | Terminated | 08/10/2019 | 28/02/2015 | Negative | Negative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02020616 | Terminated | 1 | 2013-12-01 | Terminated | stopped | null | null | null | 893,353,198,627 | Lack of Efficacy | Phase 1/Phase 2 | 31/12/2013 | Terminated | 08/10/2019 | 28/02/2015 | Negative | Negative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00263965 | Terminated | 2 | 2005-08-01 | Terminated | stopped | null | null | Phase II+ | 927,712,936,261 | The development program has been terminated | Phase 2 | 31/08/2005 | Terminated | 17/03/2008 | 31/07/2006 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00263965 | Terminated | 2 | 2005-08-01 | Terminated | stopped | null | null | Phase II+ | 927,712,936,261 | The development program has been terminated | Phase 2 | 31/08/2005 | Terminated | 17/03/2008 | 31/07/2006 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00263965 | Terminated | 2 | 2005-08-01 | Terminated | stopped | null | null | Phase II+ | 927,712,936,261 | The development program has been terminated | Phase 2 | 31/08/2005 | Terminated | 17/03/2008 | 31/07/2006 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03606694 | Recruiting | 2 | 2019-10-30 | null | null | null | null | Phase II+ | 944,892,806,230 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03606694 | Recruiting | 2 | 2019-10-30 | null | null | null | null | Phase II+ | 944,892,806,230 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT03606694 | Recruiting | 2 | 2019-10-30 | null | null | null | null | Phase II+ | 944,892,806,230 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04916093 | Completed | 4 | 2019-12-20 | null | null | Phase IV | Phase III+ | Phase II+ | 944,892,806,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04916093 | Completed | 4 | 2019-12-20 | null | null | Phase IV | Phase III+ | Phase II+ | 944,892,806,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04916093 | Completed | 4 | 2019-12-20 | null | null | Phase IV | Phase III+ | Phase II+ | 944,892,806,352 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00669864 | Completed | 4 | 2007-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 979,252,543,961 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00669864 | Completed | 4 | 2007-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 979,252,543,961 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00669864 | Completed | 4 | 2007-11-01 | null | null | Phase IV | Phase III+ | Phase II+ | 979,252,543,961 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01111955 | Completed | 2 | 2010-07-01 | null | null | null | null | Phase II+ | 979,252,544,642 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01111955 | Completed | 2 | 2010-07-01 | null | null | null | null | Phase II+ | 979,252,544,642 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01111955 | Completed | 2 | 2010-07-01 | null | null | null | null | Phase II+ | 979,252,544,642 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00437970 | Withdrawn | 4 | 2008-04-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 979,252,544,653 | Unable to secure supply of the study medication | Phase 4 | 30/04/2008 | Withdrawn | 27/05/2016 | 28/02/2009 | Logistics_Resources | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00437970 | Withdrawn | 4 | 2008-04-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 979,252,544,653 | Unable to secure supply of the study medication | Phase 4 | 30/04/2008 | Withdrawn | 27/05/2016 | 28/02/2009 | Logistics_Resources | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00437970 | Withdrawn | 4 | 2008-04-01 | Withdrawn | stopped | Phase IV | Phase III+ | Phase II+ | 979,252,544,653 | Unable to secure supply of the study medication | Phase 4 | 30/04/2008 | Withdrawn | 27/05/2016 | 28/02/2009 | Logistics_Resources | Neutral | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00712673 | Completed | 3 | 2008-06-01 | null | null | null | Phase III+ | Phase II+ | 979,252,544,660 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00712673 | Completed | 3 | 2008-06-01 | null | null | null | Phase III+ | Phase II+ | 979,252,544,660 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00712673 | Completed | 3 | 2008-06-01 | null | null | null | Phase III+ | Phase II+ | 979,252,544,660 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01935804 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 979,252,545,231 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01935804 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 979,252,545,231 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01935804 | Completed | 2 | 2009-01-01 | null | null | null | null | Phase II+ | 979,252,545,231 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00121641 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,022,202,216,452 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00121641 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,022,202,216,452 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00121641 | Completed | 3 | 2005-07-01 | null | null | null | Phase III+ | Phase II+ | 1,022,202,216,452 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04707508 | Completed | 4 | 2017-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,217,782 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04707508 | Completed | 4 | 2017-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,217,782 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT04707508 | Completed | 4 | 2017-12-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,217,782 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01365091 | Completed | 1 | 2011-06-01 | null | null | null | null | null | 1,022,202,217,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01365091 | Completed | 1 | 2011-06-01 | null | null | null | null | null | 1,022,202,217,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01365091 | Completed | 1 | 2011-06-01 | null | null | null | null | null | 1,022,202,217,922 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02235298 | Completed | 4 | 2015-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,217,970 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02235298 | Completed | 4 | 2015-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,217,970 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02235298 | Completed | 4 | 2015-09-01 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,217,970 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01864174 | Completed | 4 | 2013-06-20 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,218,477 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01864174 | Completed | 4 | 2013-06-20 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,218,477 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01864174 | Completed | 4 | 2013-06-20 | null | null | Phase IV | Phase III+ | Phase II+ | 1,022,202,218,477 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00449930 | Completed | 3 | 2007-03-01 | null | null | null | Phase III+ | Phase II+ | 1,073,741,824,567 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00449930 | Completed | 3 | 2007-03-01 | null | null | null | Phase III+ | Phase II+ | 1,073,741,824,567 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00449930 | Completed | 3 | 2007-03-01 | null | null | null | Phase III+ | Phase II+ | 1,073,741,824,567 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00425009 | Completed | 1 | 2004-01-01 | null | null | null | null | null | 1,073,741,825,303 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00425009 | Completed | 1 | 2004-01-01 | null | null | null | null | null | 1,073,741,825,303 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00425009 | Completed | 1 | 2004-01-01 | null | null | null | null | null | 1,073,741,825,303 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00449605 | Terminated | 3 | 2007-03-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,073,741,825,791 | Company decision taken in light of demands by certain national health authorities | Phase 3 | 31/03/2007 | Terminated | 16/05/2016 | 31/03/2009 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00449605 | Terminated | 3 | 2007-03-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,073,741,825,791 | Company decision taken in light of demands by certain national health authorities | Phase 3 | 31/03/2007 | Terminated | 16/05/2016 | 31/03/2009 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT00449605 | Terminated | 3 | 2007-03-01 | Terminated | stopped | null | Phase III+ | Phase II+ | 1,073,741,825,791 | Company decision taken in light of demands by certain national health authorities | Phase 3 | 31/03/2007 | Terminated | 16/05/2016 | 31/03/2009 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02192424 | Completed | 3 | 2014-07-01 | null | null | null | Phase III+ | Phase II+ | 1,082,331,759,409 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02192424 | Completed | 3 | 2014-07-01 | null | null | null | Phase III+ | Phase II+ | 1,082,331,759,409 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02192424 | Completed | 3 | 2014-07-01 | null | null | null | Phase III+ | Phase II+ | 1,082,331,759,409 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02119819 | Completed | 2 | 2014-04-01 | null | null | null | null | Phase II+ | 1,082,331,759,776 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02119819 | Completed | 2 | 2014-04-01 | null | null | null | null | Phase II+ | 1,082,331,759,776 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT02119819 | Completed | 2 | 2014-04-01 | null | null | null | null | Phase II+ | 1,082,331,759,776 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01505426 | Completed | 3 | 2011-11-28 | null | null | null | Phase III+ | Phase II+ | 1,082,331,759,930 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01505426 | Completed | 3 | 2011-11-28 | null | null | null | Phase III+ | Phase II+ | 1,082,331,759,930 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01505426 | Completed | 3 | 2011-11-28 | null | null | null | Phase III+ | Phase II+ | 1,082,331,759,930 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01485614 | Completed | 3 | 2012-02-10 | null | null | null | Phase III+ | Phase II+ | 1,082,331,760,291 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | 4 | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01485614 | Completed | 3 | 2012-02-10 | null | null | null | Phase III+ | Phase II+ | 1,082,331,760,291 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
ENSG00000065518 | MONDO_0005148 | NCT01485614 | Completed | 3 | 2012-02-10 | null | null | null | Phase III+ | Phase II+ | 1,082,331,760,291 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | EFO_0009605 | pancreas disease | Other | null | LoF tolerant | Detected in all | Tissue enhanced | from1to10 | chembl | known_drug | 413,311 |
Subsets and Splits